US, desi company tie up to develop vaaccine that can fight emerging variants

The vaccine will be developed using Dyadic’s proprietary C1-cell protein production platform. Dyadic is developing what it believes will be a potentially significant biopharmaceutical gene expression platform, based on the fungus Thermothelomyces heterothallica or C1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3bSc3v9
via IFTTT